Role of Alternative Interventional Procedures when Endo- and Epicardial Catheter Ablation Attempts for Ventricular Arrhythmias Fail
Overview
Authors
Affiliations
Background: Ventricular tachycardia (VT) refractory to antiarrhythmic drugs and standard percutaneous catheter ablation techniques portends a poor prognosis. We characterized the reasons for ablation failure and describe alternative interventional procedures in this high-risk group.
Methods And Results: Sixty-seven patients with VT refractory to 4±2 antiarrhythmic drugs and 2±1 previous endocardial/epicardial catheter ablation attempts underwent transcoronary ethanol ablation, surgical epicardial window (Epi-window), or surgical cryoablation (OR-Cryo; age, 62±11 years; VT storm in 52%). Failure of endo/epicardial ablation attempts was because of VT of intramural origin (35 patients), nonendocardial origin with prohibitive epicardial access because of pericardial adhesions (16), and anatomic barriers to ablation (8). In 8 patients, VT was of nonendocardial origin with a coexisting condition also requiring cardiac surgery. Transcoronary ethanol ablation alone was attempted in 37 patients, OR-Cryo alone in 21 patients, and a combination of transcoronary ethanol ablation and OR-Cryo (5 patients), or transcoronary ethanol ablation and Epi-window (4 patients), in the remainder. Overall, alternative interventional procedures abolished ≥1 inducible VT and terminated storm in 69% and 74% of patients, respectively, although 25% of patients had at least 1 complication. By 6 months post procedures, there was a significant reduction in defibrillator shocks (from a median of 8 per month to 1; P<0.001) and antiarrhythmic drug requirement although 55% of patients had at least 1 VT recurrence, and mortality was 17%.
Conclusions: A collaborative strategy of alternative interventional procedures offers the possibility of achieving arrhythmia control in high-risk patients with VT that is otherwise uncontrollable with antiarrhythmic drugs and standard percutaneous catheter ablation techniques.
Kautzner J, Haskova J, Cvek J, Adamira M, Peichl P Eur Heart J Case Rep. 2024; 8(8):ytae379.
PMID: 39144539 PMC: 11322737. DOI: 10.1093/ehjcr/ytae379.
Stanciulescu L, Vatasescu R Biomedicines. 2024; 12(2).
PMID: 38397868 PMC: 10886924. DOI: 10.3390/biomedicines12020266.
2023 KASNet Guidelines on Atrial Fibrillation Surgery.
Je H, Choi J, Hwang H, Kim H, Kim J, Kim H J Chest Surg. 2023; 57(1):1-24.
PMID: 37994091 PMC: 10792381. DOI: 10.5090/jcs.23.127.
Therapy Efficacy of Idiopathic Ventricular Extrasystoles: A Real Life Study.
Lonnrot A, Inkovaara J, Arola O, Penttila T, Makynen H, Aalto-Setala K J Interv Cardiol. 2023; 2023:5590422.
PMID: 37928976 PMC: 10624548. DOI: 10.1155/2023/5590422.
Jathanna N, Shanmuganathan S, Staniforth A, Jamil-Copley S Eur Heart J Case Rep. 2023; 7(5):ytad223.
PMID: 37181473 PMC: 10170528. DOI: 10.1093/ehjcr/ytad223.